Studies evaluating the effect of rEPO or an EPO derivative ARA290 have shown that rEPO inhibits macrophage activation while promoting phagocytic activity through activation of the EPOR/βcR heterodimer in experimental models of atherosclerosis and autoimmune neuritis [31, 32]. The gene discussed is BCR; the disease is atherosclerosis.